Publications of Axel Ullrich

Lutz, S. Z.; Hennige, A. M.; Peter, A.; Kovarova, M.; Totsikas, C.; Machann, J.; Krober, S. M.; Sperl, B.; Schleicher, E.; Schick, F. et al.; Heni, M.; Ullrich, A.; Haring, H.-U.; Stefan, N.: The Gly385(388)Arg Polymorphism of the FGFR4 Receptor regulates Hepatic Lipogenesis under healthy Diet. Journal of Clinical Endocrinology and Metabolism 104 (6), pp. 2041 - 2053 (2019)

Lutz, S. Z.; Falcenberg, M.; Machicao, F.; Peter, A.; Kaechele, M.; Randrianarisoa, E.; Lehn-Stefan, A.; Wagner, R.; Machann, J.; Schick, F. et al.; Heni, M.; Ullrich, A.; Fritsche, A.; Stefan, N.; Haering, H.-U.; Staiger, H.; Kantartzis, K.: Single Nucleotide Polymorphisms in the G-Protein Coupled Receptor Kinase 5 (GRK5) Gene are associated with Plasma LDL-Cholesterol Levels in Humans. Scientific Reports 8, 7745 (2018)

Szabadkai, I.; Torka, R.; Garamvolgyi, R.; Baska, F.; Gyulavari, P.; Boros, S.; Illyes, E.; Choidas, A.; Ullrich, A.; Orfi, L.: Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors. Journal of Medicinal Chemistry 61 (14), pp. 6277 - 6292 (2018)

Orfi, Z.; Waczek, F.; Baska, F.; Szabadkai, I.; Torka, R.; Hartmann, J.; Orfi, L.; Ullrich, A.: Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue. Scientific Reports 7, 44073 (2017)

Baumann, C.; Ullrich, A.; Torka, R.: GAS6 expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. Molecular oncology 11 (10), pp. 1430 - 1447 (2017)

Lutz, S. Z.; Ullrich, A.; Haering, H.-U.; Ullrich, S.; Gerst, F.: Sunitinib specifically augments glucose-induced insulin secretion. Cellular Signalling 36, pp. 91 - 97 (2017)

Xiao, Z.; Gaertner, S.; Morresi-Hauf, A.; Genzel, R.; Duell, T.; Ullrich, A.; Knyazev, P. G.: Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients. Neoplasia 19 (5), pp. 385 - 395 (2017)

Ulaganathan, V. K.; Ullrich, A.: Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants. Molecular & Cellular Oncology 3 (3), e1145176 (2016)

Onken, J.; Torka, R.; Korsing, S.; Radke, J.; Krementeskaia, I.; Nieminen, M.; Bai, X.; Ullrich, A.; Heppner, F.; Vajkoczy, P.: Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo. OncoTarget 7 (9), pp. 9876 - 9889 (2016)

Simon-Szabo, L.; Kokas, M.; Greff, Z.; Boros, S.; Banhegyi, P.; Zsakai, L.; Szantai-Kis, C.; Vantus, T.; Mandl, J.; Banhegyi, G. et al.; Valyi-Nagy, I.; Orfi, L.; Ullrich, A.; Csala, M.; Keri, G.: Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 26 (2), pp. 424 - 428 (2016)

Sommer, A.-K.; Hermawan, A.; Mickler, F. M.; Ljepoja, B.; Knyazev, P.; Braeuchle, C.; Ullrich, A.; Wagner, E.; Roidl, A.: Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases. Oncotarget 7 (31), pp. 50461 - 50476 (2016)

Grabner, A.; Amaral, A. P.; Schramm, K.; Singh, S.; Sloan, A.; Yanucil, C.; Li, J.; Shehadeh, L. A.; Hare, J. M.; David, V. et al.; Martin, A.; Fomoni, A.; Di Marco, G. S.; Kentrup, D.; Reuter, S.; Mayer, A. B.; Pavenstadt, H.; Stypmann, J.; Kuhn, C.; Hille, S.; Frey, N.; Leifheit-Nestler, M.; Richter, B.; Haffner, D.; Abraham, R.; Bange, J.; Sperl, B.; Ullrich, A.; Brand, M.; Wolf, M.; Faul, C.: Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. CELL METABOLISM 22 (6), pp. 1020 - 1032 (2015)

Gusenbauer, S.; Zanucco, E.; Knyazev, P.; Ullrich, A.: Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines. MOLECULAR CANCER 14, 54 (2015)

Stampolidis, P.; Ullrich, A.; Iacobelli, S.: LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention. ONCOGENE 31 (1), pp. 39 - 52 (2015)

Ulaganathan, V. K.; Sperl, B.; Rapp, U. R.; Ullrich, A.: Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. NATURE 528 (7583), pp. 570 - 574 (2015)

Ho, H. K.; Chua, B. T.; Wong, W.; Lim, K. S.; Teo, V.; Ong, H.-T.; Chen, X.; Zhang, W.; Hui, K. M.; Go, M. L. et al.; Ullrich, A.: Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma. MOLECULAR ONCOLOGY 8 (7), pp. 1266 - 1277 (2014)

Baska, F.; Szabadkai, I.; Sipos, A.; Breza, N.; Szantai-Kis, C.; Kekesi, L.; Garamvoelgyi, R.; Nemes, Z.; Baska, F.; Neumann, L. et al.; Torka, R.; Ullrich, A.; Keri, G.; Orfi, L.: Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors. CURRENT MEDICINAL CHEMISTRY 21 (17), pp. 1938 - 1955 (2014)

Szokol, B.; Gyulavari, P.; Kurko, I.; Baska, F.; Szantai-Kis, C.; Greff, Z.; Örfi, Z.; Petak, I.; Penzes, K.; Torka, R. et al.; Ullrich, A.; Örfi, L.; Vantus, T.; Keri, G.: Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS MEDICINAL CHEMISTRY LETTERS 5 (4), pp. 298 - 303 (2014)

Torka, R.; Penzes, K.; Gusenbauer, S.; Baumann, C.; Szabadkai, I.; Orfi, L.; Keri, G.; Ullrich, A.: Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy. NEOPLASIA 16 (4), pp. 301 - 318 (2014)

Ataseven, B.; Gunesch, A.; Eiermann, W.; Kates, R. E.; Hoegel, B.; Knyazev, P.; Ullrich, A.; Harbeck, N.: PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs. ONCOTARGETS AND THERAPY 7, pp. 1723 - 1731 (2014)